A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease

Summary

The main purpose of this study is to assess how well Donanemab is tolerated and what side effects may occur in Indian participants with early symptoms of Alzheimer's Disease (AD). For each participant, the study will last up to approximately 84 weeks and will include visits every 4 weeks.

Timeline

Start

2026-10

Primary completion

2030-07

Completion

2030-07

Drugs

Indications